Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-06-25

FDA Approved: SAVELLA — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SAVELLA (milnacipran hydrochloride) to update the labeling as part of the submission by Allergan, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SAVELLA (milnacipran hydrochloride)

Snippet

SUPPL AP for SAVELLA (MILNACIPRAN HYDROCHLORIDE)